银屑病患者血清中可溶性血小板T细胞活化抗原1的检测

Detection of Serum Soluble CD226/PTA1Level in Patients with Psoriasis Vulgaris

目的检测银屑病患者血清中可溶性血小板T细胞活化抗原1(sCD226/PTA1)的水平,初步探讨该抗原与银屑病的关系。方法银屑病患者包括疗前30例,其中活动期17例、静止期13例,疗后10例,正常人对照15例。应用双抗体夹心ELISA法测定血清中sCD226/PTA1的浓度。结果银屑病组血清中sCD226/PTA1水平(823.88±569.93pg/mL)显著高于正常人(120.45±58.41pg/mL),t= 4.41,P<0.001。活动期(1036.07±598.97pg/mL)更高,依次高于静止期(546.39±399.28pg/mL)和正常人。疗后组(263.16±207.3pg/mL)显著低于相应的疗前组(751.51±648.07pg/mL),t= 3.42,P<0.005。与正常人比较,疗后组值仍偏高,但差异无显著性,t=2.02,P>0.05。结论银屑病患者血清中存在高水平的sCD226/PTA1,并在活动期、静止期及疗后呈现出不同的变化。提示CD226/PTA1可能参与银屑病的病理过程。

Objective To determine the serum soluble CD226/PTA1(sCD226/PTA1)level in pa-tients with psoriasis vulgaris.Methods Serum sCD226/PTA1level was measured by sandwich ELISA in30patients with psoriasis vulgaris before treatment(17patients in active stage and13in inactive stage),10patients after treatment,and15healthy individuals as a control.Results Serum sCD226/PTA1level was significantly increased in patients with psoriasis compared with that in healthy controls(P< 0.001).Serum sCD226/PTA1level was significantly higher in active stage patients than that in inactive stage patients(P< 0.05).The result of10self-comparison paired data showed that serum sCD226/PTA1level was significantly decreased after treatment(P< 0.005).Conclusion Serum sCD226/PTA1level is significantly increased in psoriatic patients and the level varies in different stages.These data suggest that CD226/PTA1may be in-volved in the pathogenesis of psoriasis.